We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Refinitiv and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from our Featured Companies page.
Oxford BioDynamics
FY25 results: delivering despite the challengesHUTCHMED
Pipeline potential underpins long-term growth prospectsScancell
Latest SCOPE data confirm durable improvementScancell
Abundant development opportunities in immuno-oncologyOxford BioDynamics
£7m fundraise secures near-term futureAvacta
FAP-Dox cardiotox impresses; crucial £16m fundraiseAvacta
Dual payload pre|CISION unveiled at EORTC-NCI-AACRHUTCHMED
ESMO: fruquintinib’s significant benefit in kidney cancerOxford BioDynamics
New EpiSwitch test for Chronic Fatigue SyndromeAvacta
Key faridox data and FAP-EXd Phase I start on the horizon